PT-141 (Bremelanotide)

Sexual Health & Libido
Phase 4
FDA Approved

PT-141 (Bremelanotide) is a hormone receptor activator that works directly in the brain, unlike blood flow-based medications for sexual dysfunction. It is FDA-approved as Vyleesi for treating hypoactive sexual desire disorder (HSDD) in premenopausal women.

Last updated March 6, 2026
102 PubMed-Verified Studies
Very Popular
Research-Driven Dosage Reports
RouteSubcutaneous (SC) · Intranasal
Dose1–2 mg
FrequencyAs needed (max 8×/month)
DurationOngoing as needed

Based on published research literature.

Swiss Chems|Exclusive Offer
Coupon
10%
Off

Use our affiliate link and code PEPTIDEWIKI at checkout to unlock your 10% discount, every time you use the code.

Shop Now

For research purposes only. PeptideWiki may earn a commission at no extra cost to you.

Overview of PT-141 (Bremelanotide)

Activates melanocortin receptors in the central nervous system to enhance neural pathways involved in sexual desire and arousal.

Sexual function / libido

Activates MC3R and MC4R receptors in the hypothalamus and limbic system, areas involved in sexual desire, arousal, and motivation.

Works directly on brain pathways to enhance sexual desire, a different mechanism from PDE-5 inhibitors that work peripherally on blood flow.

Influences dopaminergic and oxytocinergic pathways (proposed), affecting sexual response and pair bonding.

Gender-specific effects

Produces dose-dependent erectile responses in men with organic erectile dysfunction, and is effective even in those unresponsive to PDE-5 inhibitors.

Increases desire and reduces distress associated with low sexual desire in premenopausal women with HSDD, an FDA-approved indication

Read Full PT-141 (Bremelanotide) Dosage Guide

Research-backed dosing protocols, timing, and administration details

Browse more in this category

Sexual Health & Libido